SCHEMBL1471283

SCHEMBL1471283

Cc1cccc(N2C(=O)C=C(c3ccccc3)C2=O)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
GAA P10253 4/20 0.43
LMNA P02545 3/20 0.43
ALDH1A1 P00352 2/20 0.43
CCR6 P51684 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HTT P42858 1/20 0.43
KDM5A P29375 1/20 0.42
HPGD P15428 1/20 0.42
ALOX12 P18054 1/20 0.42
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42
MGLL Q99685 2/20 0.41
RGS4 P49798 1/20 0.40
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TP53 P04637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CFTR P13569 1/20 0.37
TYMS P04818 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1473625 0.87 MAPT (0.45) MAPTGAALMNAALDH1A1NPSR1
SCHEMBL1471818 0.78 MAPT (0.49) MAPTGAALMNAALDH1A1CCR6
SCHEMBL29671041 0.77 POLB (0.54) MAPTGAALMNAALDH1A1CCR6
SCHEMBL9156042 0.77 POLB (0.54) MAPTGAALMNAALDH1A1CCR6
SCHEMBL1473515 0.76 MGLL (0.53) MAPTGAALMNAALDH1A1CCR6
SCHEMBL1471696 0.76 MGLL (0.53) MAPTGAALMNAALDH1A1CCR6
SCHEMBL1471840 0.76 MGLL (0.57) MAPTGAAALDH1A1CCR6NPSR1
SCHEMBL1471424 0.75 LMNA (0.45) MAPTGAALMNAALDH1A1NPSR1
SCHEMBL17475492 0.74 MAPT (0.48) MAPTGAALMNAALDH1A1CCR6
SCHEMBL1471202 0.73 MAPT (0.48) MAPTGAALMNAALDH1A1CCR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP claimed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US claimed
WO-2016144352-A2 THERAPEUTIC COMPOSITIONS INCLUDING ACRYLAMIDO COMPOUNDS OR PHENYL-SUBSTITUTED MALEIMIDE COMPOUNDS, VARIANTS THEREOF AND METHODS OF USING THE SAME STEALTH PEPTIDES INTERNATIONAL, INC. (MC) 2016-09-15 WO disclosed
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US disclosed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP disclosed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US disclosed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP disclosed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CYC1, MTPN, TXN2 MAPT 1947/4885GAA 1158/4885LMNA 1640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.